Benuvia Therapeutics

Benuvia Therapeutics products

C – Cannabidiol (CBD)

• Generic name: Cannabidiol

• Indication: Investigated for epilepsy, anxiety, pain, inflammation

• Typical use: Oral or sublingual solutions; dose ranges in trials ~5–20 mg/kg/day

D – Dronabinol

• Generic name: Dronabinol (synthetic Δ9-THC)

• Indication: Chemotherapy-induced nausea/vomiting; anorexia in AIDS patients

• Dose: 2.5–10 mg orally, 2–3 times daily

D – DMT (Dimethyltryptamine)

• Generic name: N,N-Dimethyltryptamine

• Indication: Investigational psychedelic for depression, PTSD

• Dose: Administered in controlled clinical settings; studied IV bolus/infusion

F – 5-MeO-DMT

• Generic name: 5-Methoxy-N,N-Dimethyltryptamine

• Indication: Investigational psychedelic for anxiety, substance use disorders

• Dose: Inhaled or intranasal microgram-level doses under study

M – MDMA

• Generic name: 3,4-Methylenedioxymethamphetamine

• Indication: PTSD (Phase III clinical studies)

• Dose: 75–125 mg single oral doses under supervision in trials

P – Psilocybin

• Generic name: Psilocybin

• Indication: Treatment-resistant depression, major depressive disorder, substance use disorders

• Dose: Investigational oral dose ~25–30 mg in clinical trials

P – Psilocin

• Generic name: Psilocin (active metabolite of psilocybin)

• Indication: Same as psilocybin (psychedelic therapy)

• Dose: Studied orally; milligram-level dosing

S – Sublingual Spray Formulations

• Generic names: Dronabinol, Diclofenac, Rizatriptan, Ondansetron

• Indication: Pain, nausea/vomiting, migraine

• Dose: Delivered as rapid-acting sprays; dosing varies by molecule (e.g., rizatriptan spray ~10 mg per dose)